Astellas Engineered Small Molecules US, Incorporated

Tango Therapeutics, Inc.

Xinyuan Wu

Bharat Lagu

Arthur F Kluge

John Patrick Maxwell

David Joseph Guerin

Iwona Wrona

Bertrand L Chenard

Eric Bell

Margaret Biddle

Takashi Ogiyama

Guohua Liang

Lisa Mcqueen

Santosh S Kulkarni

Sanjita Sasmal

Qingyi Li

Bertand L Chenard

Christopher M Liu

Matthew F Baevsky

Andrew J Jackson

Jared Smit

Richard Alan Earl

Brett Cowans

Blaise S Lippa

One embodiment of the invention is a compound represented by Formula I: or a pharmaceutically acceptable salt thereof. The variables in Formula I are defined herein. Compounds of Formula I are CD38 inhibitors, which can be used to treat a disease or condition in a subject that benefits from an increase in NAD+ or to treat a mitochondrial disorder in a subject.

CD38 inhibitors

The present invention is related to compounds of structure (I) as heme oxygenase 1 (HMOX 1) inducers. (Formula I) The present invention is also related a method of controlling the activity or the amount, or both the activity and the amount, of heme-oxygenase 1 in a mammalian subject. The definitions of the variables are provided herein.

HMOX1 inducers

Described herein are novel compounds, compositions and methods for treatment of diseases including cancer using such compounds, compositions, and methods. The compounds include those of Formula (I):

HDAC inhibitors and therapeutic use thereof

Growing community of inventors

Chestnut Hill, MA, United States of America

Xinyuan Wu